000 02094 a2200565 4500
005 20250516121239.0
264 0 _c20130624
008 201306s 0 0 eng d
022 _a2567-689X
024 7 _a10.1160/TH12-04-0228
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aMani, Helen
245 0 0 _aEx vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions.
_h[electronic resource]
260 _bThrombosis and haemostasis
_cJan 2013
300 _a127-36 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAdministration, Oral
650 0 4 _aAnticoagulants
_xadministration & dosage
650 0 4 _aArthroplasty, Replacement, Hip
_xadverse effects
650 0 4 _aArthroplasty, Replacement, Knee
_xadverse effects
650 0 4 _aBiomarkers
_xblood
650 0 4 _aBlood Coagulation
_xdrug effects
650 0 4 _aBlood Coagulation Factors
_xantagonists & inhibitors
650 0 4 _aBlood Coagulation Tests
_xmethods
650 0 4 _aChromatography, High Pressure Liquid
650 0 4 _aChromogenic Compounds
650 0 4 _aDrug Administration Schedule
650 0 4 _aEnzyme-Linked Immunosorbent Assay
650 0 4 _aFactor Xa
_xmetabolism
650 0 4 _aFactor Xa Inhibitors
650 0 4 _aFalse Positive Reactions
650 0 4 _aHumans
650 0 4 _aMorpholines
_xadministration & dosage
650 0 4 _aNephelometry and Turbidimetry
650 0 4 _aPredictive Value of Tests
650 0 4 _aReproducibility of Results
650 0 4 _aRivaroxaban
650 0 4 _aTablets
650 0 4 _aTandem Mass Spectrometry
650 0 4 _aThiophenes
_xadministration & dosage
650 0 4 _aThrombophilia
_xblood
650 0 4 _aThrombosis
_xblood
650 0 4 _aTime Factors
650 0 4 _aTreatment Outcome
700 1 _aHesse, Christian
700 1 _aStratmann, Gertrud
700 1 _aLindhoff-Last, Edelgard
773 0 _tThrombosis and haemostasis
_gvol. 109
_gno. 1
_gp. 127-36
856 4 0 _uhttps://doi.org/10.1160/TH12-04-0228
_zAvailable from publisher's website
999 _c22250851
_d22250851